Arterium Corporation continues its expansion on Azerbaijan’s market

11 серпня 2016, 13:52

Arterium Corporation continues developing its business on foreign markets. In June 2014, Proneuro Solution for Injection and Proneuro Oral Solution were approved in the Republic of Azerbaijan.

Proneuro is a prescription drug and can be recommended to patients with acute phase of cerebral circulation disorder and complications and sequelae of cerebral circulation disorder. This drug is effective in the treatment of traumatic brain injuries and their consequences, cognitive, sensitivity, motor and neurological disorders caused by cerebral pathology of degenerative and vascular origin.

Ukrainian healthcare professionals and pharmacists know this drug as Neuroxon. “Citicoline products are now very important and of high demand in Azerbaijan. It is these drugs that have proven high efficiency and safety for the treatment of stroke. Proneuro is a promising product in terms of entering the market because it is an affordable product with established equivalence to the original drug” – says Oleg Kiyashko, Head of Representative Office of Arterium Corporation to Azerbaijan.

Twenty-eight products exported by Arterium Corporation and affiliates are now approved in Azerbaijan including Gerpevir, Thiotriazolin, Urolesan, Thiocetam, and L-lysine aescinat.

Arterium Corporation opened its Representative Office to Azerbaijan in 2013 to support sales at thismarket.

For more information on Neuroxon, please refer to Patient Leaflet (Neuroxon Solution for Injection, Neuroxon Oral Solution, and Neuroxon Tablets).

For more information on Proneuro, please refer to Patient Leaflet (Proneuro Solution for Injection and Proneuro Oral Solution).